Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts-Reference-Cited by-同舟云学术

Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts

Published:2005 Issue:11 Volume:7 Page:1482-1491
ISSN:1099-498X
Container-title:The Journal of Gene Medicine
language:en
Short-container-title:J. Gene Med.

Author:

Friso Adelaide,Tomanin Rosella,Alba Sabrina,Gasparotto Nicoletta,Puicher Elisabetta Piller,Fusco Mariella,Hortelano Gonzalo,Muenzer Joseph,Marin Oriano,Zacchello Franco,Scarpa Maurizio

Publisher

Wiley

Subject

Genetics(clinical),Drug Discovery,Genetics,Molecular Biology,Molecular Medicine

Reference51 articles.

1. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher’s disease

2. Enzyme-Replacement Therapy in Mucopolysaccharidosis I

3. Enzyme replacement therapy in mucopolysaccharidosis type I: Progress and emerging difficulties

4. Metabolic correction and cross-correction of mucopolysaccharidosis type II (Hunter syndrome) by retroviral-mediated gene transfer and expression of human iduronate-2-sulfatase.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy;Journal of Molecular Medicine;2022-07-11

2. Differences in MPS I and MPS II Disease Manifestations;International Journal of Molecular Sciences;2021-07-23

3. Therapeutic Options for Mucopolysaccharidosis II (Hunter Disease);Current Pharmaceutical Design;2020-11-27

4. Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment;International Journal of Molecular Sciences;2020-02-13

5. Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles;International Journal of Molecular Sciences;2019-04-24